GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeraMED Ltd (FRA:1I4) » Definitions » EPS without NRI

HeraMED (FRA:1I4) EPS without NRI : €-0.02 (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is HeraMED EPS without NRI?

HeraMED's earnings per share without non-recurring items for the six months ended in Jun. 2024 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.02.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 10.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for HeraMED's EPS without NRI or its related term are showing as below:

FRA:1I4' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 10.6   Med: 14.6   Max: 31.8
Current: 10.6

During the past 6 years, HeraMED's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 31.80% per year. The lowest was 10.60% per year. And the median was 14.60% per year.

FRA:1I4's 3-Year EPS without NRI Growth Rate is ranked better than
53.37% of 697 companies
in the Medical Devices & Instruments industry
Industry Median: 9 vs FRA:1I4: 10.60

HeraMED's EPS (Diluted) for the six months ended in Jun. 2024 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.02.

HeraMED's EPS (Basic) for the six months ended in Jun. 2024 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.02.


HeraMED EPS without NRI Historical Data

The historical data trend for HeraMED's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeraMED EPS without NRI Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.03 -0.02 -0.03 -0.02 -0.02

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of HeraMED's EPS without NRI

For the Medical Devices subindustry, HeraMED's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeraMED's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where HeraMED's PE Ratio without NRI falls into.



HeraMED EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeraMED  (FRA:1I4) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


HeraMED EPS without NRI Related Terms

Thank you for viewing the detailed overview of HeraMED's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


HeraMED Business Description

Traded in Other Exchanges
Address
201, 697 Burke Road, Suite 4, Camberwell, VIC, AUS, 3124
HeraMED Ltd is engaged in developing, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heartbeat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart and connected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR). It is also focused on the commercialization and deployment of its HeraCARE pregnancy monitoring solution. Geographically, the company generates a majority of its revenue from the United States of America followed by Australia and Israel.

HeraMED Headlines

No Headlines